Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18944456 | AQUEOUS SUSPENSION SUITABLE FOR ORAL ADMINISTRATION | November 2024 | June 2025 | Allow | 7 | 1 | 0 | Yes | No |
| 18670599 | METHOD OF TREATMENT OF DEPRESSED PATIENTS WITH POOR COGNITION AND SELECTION OF OTHER PATIENTS BENEFITING FROM A BENZYLPIPERAZINE-AMINOPYRIDINE AGENT | May 2024 | March 2025 | Abandon | 10 | 1 | 0 | No | No |
| 18615512 | COMPOSITIONS AND METHODS FOR ADMINISTERING PALTUSOTINE TO PATIENTS WITH HEPATIC IMPAIRMENT | March 2024 | September 2024 | Allow | 6 | 1 | 0 | Yes | No |
| 18588191 | QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE | February 2024 | June 2024 | Allow | 4 | 0 | 0 | Yes | No |
| 18426972 | AQUEOUS SUSPENSION SUITABLE FOR ORAL ADMINISTRATION | January 2024 | August 2024 | Allow | 6 | 1 | 0 | Yes | No |
| 18405189 | NOVEL SHORT-ACTING PSYCHOACTIVE COMPOUNDS OF THE MDMA CLASS | January 2024 | June 2025 | Abandon | 18 | 1 | 0 | No | No |
| 18404037 | USP9X Inhibitors | January 2024 | July 2024 | Allow | 6 | 0 | 0 | Yes | No |
| 18524381 | GLUTARIMIDE-CONTAINING KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF | November 2023 | July 2024 | Allow | 8 | 1 | 1 | Yes | No |
| 18384489 | NEEM FOR TREATMENT OF RLS | October 2023 | May 2024 | Allow | 7 | 0 | 0 | Yes | No |
| 18491200 | Inhibition of Lysine Demethylase 1 (Lsd1) Induces Differentiation of Hair Cells | October 2023 | February 2025 | Abandon | 16 | 1 | 0 | No | No |
| 18485086 | USE OF DEXPRAMIPEXOLE FOR THE TREATMENT OF MODERATE TO SEVERE ASTHMA | October 2023 | September 2024 | Abandon | 11 | 1 | 0 | No | No |
| 18485082 | USE OF DEXPRAMIPEXOLE FOR THE TREATMENT OF MODERATE TO SEVERE ASTHMA | October 2023 | August 2024 | Abandon | 10 | 1 | 0 | No | No |
| 18376346 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | October 2023 | August 2024 | Allow | 11 | 0 | 1 | Yes | No |
| 18240200 | 1,3-BENZOTHIAZOL-2-YL-N'-[(3-PHENYLPROP-2-ENOYL)OXY]ETHANIMIDAMIDE AS AN ANTICANCER AND ANTIMICROBIAL COMPOUND | August 2023 | November 2023 | Allow | 3 | 0 | 0 | Yes | No |
| 18240076 | PHARMACEUTICAL COMPOSITIONS COMPRISING (S)-4-(4-(4-(((2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLIN-4-YL)OXY)METHYL)BENZYL)PIPERAZIN-1-YL)-3-FLUOROBENZONITRILE AND METHODS OF USING THE SAME | August 2023 | April 2024 | Allow | 7 | 0 | 0 | Yes | No |
| 18239273 | 1,3-BENZOTHIAZOL-2-YL-N'-[(NAPHTHALENE-1-CARBONYL)OXY]ETHANIMIDAMIDE AS AN ANTITUMOR AND ANTIMICROBIAL COMPOUND | August 2023 | November 2023 | Allow | 2 | 0 | 0 | Yes | No |
| 18455757 | COMBINATIONS COMPRISING BREXPIPRAZOLE OR A SALT THEREOF AND A SECOND DRUG FOR USE IN THE TREATMENT OF A CNS DISORDER | August 2023 | January 2025 | Abandon | 16 | 1 | 0 | No | No |
| 18229474 | QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE | August 2023 | January 2024 | Allow | 6 | 1 | 0 | No | No |
| 18209334 | NOVEL SHORT-ACTING PSYCHOACTIVE COMPOUNDS OF THE MDMA CLASS | June 2023 | December 2023 | Allow | 6 | 1 | 0 | Yes | No |
| 18326505 | REELIN/VEGF-C PRODUCTION/ACTIVATION PROMOTER AND SKIN EXTERNAL COMPOSITION USING THE SAME | May 2023 | June 2024 | Allow | 13 | 2 | 0 | Yes | No |
| 18199634 | QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE | May 2023 | September 2023 | Allow | 4 | 1 | 0 | Yes | No |
| 18198373 | PHARMACEUTICAL COMPOSITIONS AND ORAL DOSAGE FORMS OF KETAMINE DERIVATIVES | May 2023 | May 2025 | Allow | 24 | 2 | 0 | No | No |
| 18313991 | HOST DEFENSE PROTEIN (HDP) MIMETICS FOR PROPHYLAXIS AND/OR TREATMENT OF INFLAMMATORY DISEASES OF THE GASTROINTESTINAL TRACT | May 2023 | January 2025 | Abandon | 20 | 1 | 0 | No | No |
| 18136484 | STABILIZATION OF EPINEPHRINE FORMULATIONS | April 2023 | April 2025 | Allow | 24 | 2 | 0 | Yes | No |
| 18300504 | AQUEOUS SUSPENSION SUITABLE FOR ORAL ADMINISTRATION | April 2023 | October 2023 | Allow | 6 | 1 | 0 | Yes | No |
| 18095161 | USP9X INHIBITORS | January 2023 | March 2024 | Abandon | 14 | 1 | 0 | No | No |
| 18059350 | METHODS AND DEVICES FOR TREATMENT OF EYELID PTOSIS | November 2022 | August 2023 | Allow | 8 | 1 | 1 | Yes | No |
| 17988230 | USP9X INHIBITORS | November 2022 | March 2023 | Allow | 4 | 0 | 0 | Yes | No |
| 17985504 | PHARMACEUTICAL COMPOSITION COMPRISING OXIDIZABLE BIPHENOL AND MANGANESE PORPHYRIN, AND METHOD OF USING THE SAME | November 2022 | October 2024 | Allow | 23 | 1 | 1 | Yes | No |
| 17958169 | THERAPEUTIC USES OF L-4-CHLOROKYNURENINE | September 2022 | February 2025 | Abandon | 29 | 1 | 1 | No | No |
| 17935408 | SMALL MOLECULE ANTIVIRAL DRUG TREATMENT FOR HUMAN PAPILLOMAVIRUS INFECTIONS | September 2022 | August 2023 | Allow | 11 | 1 | 1 | Yes | No |
| 17949300 | EXTENDED RELEASE COMPOSITIONS COMPRISING PYRIDOSTIGMINE | September 2022 | September 2023 | Abandon | 12 | 1 | 0 | No | No |
| 17896483 | METHODS OF ADMINISTERING GAMMA-HYDROXYBUTYRATE COMPOSITIONS WITH DIVALPROEX SODIUM | August 2022 | August 2023 | Abandon | 12 | 1 | 0 | Yes | No |
| 17887049 | PHARMACEUTICAL COMPOSITIONS AND ORAL DOSAGE FORMS OF KETAMINE DERIVATIVES | August 2022 | February 2023 | Allow | 6 | 1 | 1 | Yes | No |
| 17871922 | BUFFER- AND CHELATOR-FREE, STABLE OPHTHALMOLOGICAL COMPOSITIONS OF KETOROLAC AND PHENYLEPHRINE AND APPLICATIONS THEREOF | July 2022 | July 2023 | Abandon | 12 | 1 | 0 | No | No |
| 17866942 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | July 2022 | July 2023 | Allow | 12 | 1 | 0 | Yes | No |
| 17851165 | Treatment of Dermal Cytokine Storm Syndromes | June 2022 | July 2024 | Abandon | 24 | 4 | 0 | No | Yes |
| 17782850 | SPIRO COMPOUND SERVING AS ERK INHIBITOR, AND APPLICATION THEREOF | June 2022 | April 2025 | Allow | 34 | 0 | 0 | Yes | No |
| 17824993 | AQUEOUS SUSPENSION SUITABLE FOR ORAL ADMINISTRATION | May 2022 | January 2023 | Allow | 8 | 1 | 0 | Yes | No |
| 17748475 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY | May 2022 | August 2022 | Allow | 3 | 1 | 0 | Yes | No |
| 17772878 | SYNERGISTIC NUTRITIONAL COMPOSITIONS FOR TREATING CEREBROVASCULAR DISEASES | April 2022 | August 2023 | Allow | 15 | 2 | 0 | Yes | No |
| 17721827 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY | April 2022 | July 2022 | Allow | 3 | 0 | 0 | Yes | No |
| 17717516 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY | April 2022 | July 2022 | Allow | 3 | 0 | 0 | Yes | No |
| 17716796 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY | April 2022 | July 2022 | Allow | 3 | 0 | 0 | Yes | No |
| 17713872 | FORMULATIONS OF FOSAPREPITANT AND APREPITANT | April 2022 | August 2024 | Abandon | 28 | 2 | 0 | No | Yes |
| 17657832 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY | April 2022 | June 2022 | Allow | 2 | 0 | 0 | Yes | No |
| 17712970 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY | April 2022 | June 2022 | Allow | 3 | 0 | 0 | Yes | No |
| 17705834 | Coated Particles and Their Uses | March 2022 | January 2023 | Allow | 10 | 0 | 1 | Yes | No |
| 17705930 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY | March 2022 | June 2022 | Allow | 2 | 0 | 0 | Yes | No |
| 17591621 | Conjugates And Conjugating Reagents Comprising A Linker That Includes At Least Two (-CH2-CH2-O-) Units In A Ring | February 2022 | August 2023 | Allow | 19 | 1 | 1 | Yes | No |
| 17579069 | SMALL MOLECULE ANTIVIRAL DRUG TREATMENT FOR HUMAN PAPILLOMAVIRUS INFECTIONS | January 2022 | February 2023 | Allow | 13 | 2 | 0 | Yes | No |
| 17621567 | RHO KINASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | December 2021 | March 2025 | Allow | 39 | 0 | 0 | Yes | No |
| 17456459 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY | November 2021 | February 2022 | Allow | 3 | 0 | 0 | Yes | No |
| 17456146 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY | November 2021 | March 2022 | Allow | 3 | 0 | 0 | Yes | No |
| 17612757 | N-CONTAINING HETEROARYL DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCER | November 2021 | February 2025 | Allow | 39 | 0 | 0 | Yes | No |
| 17454110 | PHARMACEUTICALLY ACCEPTABLE SALTS OF MESDOPETAM AND USES THEREOF | November 2021 | November 2023 | Abandon | 24 | 1 | 0 | No | No |
| 17518608 | 2-[Thiophen-2-yl)formamido]-N-(phenyl)-2-methylpropanamide derivatives and the use therof as medicament | November 2021 | February 2023 | Allow | 15 | 0 | 1 | Yes | No |
| 17498507 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY | October 2021 | September 2023 | Abandon | 23 | 1 | 0 | No | No |
| 17486634 | COMPOSITIONS COMPRISING TACROLIMUS FOR THE TREATMENT OF INTRAOCULAR INFLAMMATORY EYE DISEASES | September 2021 | May 2025 | Abandon | 44 | 4 | 0 | No | No |
| 17406895 | METHOD FOR TREATING ATHLETES SUBJECT TO PATHOLOGICAL CARDIAC HYPERTROPHY BY ADMINISTERING NIGELLA SATIVA | August 2021 | May 2024 | Abandon | 33 | 2 | 1 | Yes | No |
| 17405429 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY | August 2021 | April 2022 | Allow | 8 | 1 | 0 | Yes | No |
| 17431336 | METHODS AND COMPOSITIONS FOR TREATING LYSOSOMAL STORAGE DISORDERS: AMBROXOL AS TREATMENT AGENT FOR MUCOPOLYSACCHARIDOSES III (SANFILIPPO SYNDROME) | August 2021 | May 2025 | Allow | 45 | 1 | 1 | Yes | No |
| 17430903 | SUBSTITUTED AMIDE COMPOUNDS USEFUL AS FARNESOID X RECEPTOR MODULATORS | August 2021 | February 2025 | Allow | 42 | 1 | 0 | Yes | No |
| 17401642 | QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE | August 2021 | July 2023 | Allow | 23 | 1 | 1 | Yes | No |
| 17402419 | COMPOSITIONS FOR AND METHODS OF INHIBITING SARS-COV2 INFECTION | August 2021 | February 2024 | Allow | 30 | 1 | 1 | Yes | No |
| 17401371 | QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE | August 2021 | May 2023 | Allow | 21 | 1 | 1 | Yes | No |
| 17430409 | PYRROLIDINE OREXIN RECEPTOR AGONISTS | August 2021 | April 2025 | Allow | 44 | 2 | 1 | Yes | No |
| 17400359 | DOSAGE FORM FOR VAPORIZATION AND SMOKING | August 2021 | July 2023 | Allow | 23 | 0 | 0 | Yes | No |
| 17398156 | METHOD AND COMPOSITION FOR TREATING CORONA VIRUS, INFLUENZA, AND ACUTE RESPIRATORY DISTRESS SYNDROME | August 2021 | June 2025 | Abandon | 47 | 4 | 1 | No | No |
| 17395222 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY | August 2021 | April 2022 | Allow | 8 | 1 | 0 | Yes | No |
| 17394398 | Method for the augmentation of substance abuse therapies using cannabinoid formulations | August 2021 | November 2023 | Abandon | 27 | 1 | 0 | No | No |
| 17427112 | IMMUNOMODULATORS, COMPOSITIONS AND METHODS THEREOF | July 2021 | September 2024 | Allow | 37 | 0 | 1 | Yes | No |
| 17426898 | FIBROSIS DRUG | July 2021 | September 2024 | Allow | 38 | 2 | 0 | Yes | No |
| 17425461 | CARBAMATE DERIVATIVES AND USES THEREOF | July 2021 | May 2025 | Abandon | 46 | 0 | 1 | No | No |
| 17366007 | COMPOSITIONS AND METHODS FOR INDUCING BIOLOGICAL MIMICRY IN A MAMMAL FOR THE PREVENTION AND/OR TREATMENT OF COVID-19 AND OTHER DISEASES | July 2021 | September 2023 | Abandon | 26 | 0 | 1 | No | No |
| 17420181 | TESOFENSINE FOR REDUCTION OF BODY WEIGHT IN PRADER-WILLI PATIENTS | July 2021 | May 2025 | Abandon | 46 | 1 | 1 | No | No |
| 17418353 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 AND USES THEREOF | June 2021 | December 2024 | Allow | 42 | 1 | 1 | Yes | No |
| 17357388 | METHOD OF TREATING PATIENTS INFECTED WITH SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2) | June 2021 | January 2023 | Allow | 19 | 1 | 0 | No | No |
| 17417182 | HETEROCYCLIC DERIVATIVES AS NAV1.7 AND NAV1.8 BLOCKERS | June 2021 | July 2024 | Allow | 37 | 0 | 1 | Yes | No |
| 17309712 | ESTROGEN RECEPTOR ANTAGONIST | June 2021 | October 2024 | Allow | 40 | 1 | 0 | Yes | No |
| 17413815 | METHODS FOR THE TREATMENT OF DEPRESSION | June 2021 | December 2024 | Abandon | 42 | 1 | 0 | No | No |
| 17299137 | Functionalised Amine Derivatives as IL-17 Modulators | June 2021 | May 2025 | Allow | 48 | 2 | 1 | Yes | No |
| 17336613 | SUBLINGUAL FORMULATION FOR HYPOTENSION AND SYNCOPE | June 2021 | October 2024 | Abandon | 41 | 3 | 1 | No | No |
| 17335772 | METAL DI-AMINO ACID CHELATES OR METAL TRI-AMINO ACID CHELATES | June 2021 | January 2025 | Abandon | 44 | 3 | 1 | No | No |
| 17296764 | Inhibition of Lysine Demethylase 1 (Lsd1) Induces Differentiation of Hair Cells | May 2021 | December 2023 | Abandon | 31 | 1 | 0 | No | No |
| 17296553 | COMPOSITIONS FOR TREATMENT OF SYMPHYSIOLYSIS | May 2021 | December 2024 | Abandon | 43 | 2 | 1 | No | No |
| 17296601 | 4-AMINO OR 4-ALKOXY-SUBSTITUTED ARYL SULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | May 2021 | October 2024 | Allow | 41 | 1 | 1 | No | No |
| 17296617 | PHARMACEUTICAL FORMULATIONS COMPRISING AN AMINOINDANE COMPOUND | May 2021 | June 2025 | Abandon | 49 | 2 | 1 | No | No |
| 17293755 | METHOD OF TREATING REFRACTORY EPILEPSY SYNDROMES USING FENFLURAMINE ENANTIOMERS | May 2021 | January 2024 | Abandon | 32 | 1 | 0 | No | No |
| 17246400 | METHODS OF PROPHYLAXIS AND TREATMENT OF COVID-19 USING AZOXIMER BROMIDE | April 2021 | April 2023 | Abandon | 24 | 1 | 0 | No | No |
| 17290012 | COMBINATION OF M-OPIOID RECEPTOR (MOR) MODULATORS FOR PREVENTING AND TREATING PAIN, SUICIDALITY AND MENTAL DISORDERS | April 2021 | June 2024 | Abandon | 38 | 1 | 1 | No | No |
| 17289601 | INJECTABLE FORMULATIONS OF ANESTHETICS FOR ANY PATHOLOGICAL PAIN | April 2021 | February 2025 | Allow | 46 | 3 | 1 | Yes | No |
| 17287837 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | April 2021 | January 2024 | Abandon | 33 | 0 | 1 | No | No |
| 17286155 | METHODS OF TREATING CENTRAL NERVOUS SYSTEM DISORDERS | April 2021 | October 2024 | Abandon | 42 | 0 | 1 | No | No |
| 17231455 | METHODS OF ADMINISTERING GAMMA-HYDROXYBUTYRATE COMPOSITIONS WITH DIVALPROEX SODIUM | April 2021 | August 2023 | Abandon | 28 | 1 | 1 | Yes | No |
| 17309017 | COMPOSITIONS AND METHODS FOR ACTIVATING NRF2-DEPENDENT GENE EXPRESSION | April 2021 | March 2024 | Allow | 35 | 1 | 1 | Yes | No |
| 17284131 | ESKETAMINE FOR USE IN TREATING MAJOR DEPRESSIVE DISORDER | April 2021 | March 2025 | Allow | 47 | 2 | 0 | Yes | No |
| 17224231 | COMPOSITIONS AND METHODS FOR THE PROPHYLAXIS AND/OR TREATMENT OF VIRAL INFECTIONS OR CONDITIONS ASSOCIATED THEREWITH | April 2021 | February 2024 | Abandon | 34 | 2 | 0 | No | No |
| 17215292 | HAIR COMPOSITIONS AND METHODS OF USE THEREOF | March 2021 | August 2022 | Allow | 17 | 0 | 0 | Yes | No |
| 17278393 | POSITIVE ALLOSTERIC MODULATORS OF GABAA RECEPTOR | March 2021 | October 2023 | Allow | 31 | 0 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner BAEK, BONG-SOOK.
With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 3.8% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner BAEK, BONG-SOOK works in Art Unit 1611 and has examined 385 patent applications in our dataset. With an allowance rate of 55.1%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 27 months.
Examiner BAEK, BONG-SOOK's allowance rate of 55.1% places them in the 10% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by BAEK, BONG-SOOK receive 1.75 office actions before reaching final disposition. This places the examiner in the 52% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by BAEK, BONG-SOOK is 27 months. This places the examiner in the 55% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a +76.4% benefit to allowance rate for applications examined by BAEK, BONG-SOOK. This interview benefit is in the 99% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 23.2% of applications are subsequently allowed. This success rate is in the 22% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 17.1% of cases where such amendments are filed. This entry rate is in the 12% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants request a pre-appeal conference (PAC) with this examiner, 200.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 92% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 55.6% of appeals filed. This is in the 22% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.
When applicants file petitions regarding this examiner's actions, 39.4% are granted (fully or in part). This grant rate is in the 37% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.
Examiner's Amendments: This examiner makes examiner's amendments in 2.1% of allowed cases (in the 78% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 0% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.